Nautilus Biotechnology (NAUT) Operating Expenses (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Operating Expenses data on file, last reported at $16.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 14.43% year-over-year to $16.1 million; the trailing twelve-month figure through Mar 2026 stood at $64.1 million (down 18.54% YoY), and the FY2025 full-year result was $66.8 million, down 17.97% from the prior year.
• Operating Expenses grew to $16.1 million in Q1 2026, from $15.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $21.6 million in Q1 2024 to a low of $15.4 million in Q4 2025.
• A 5-year average of $17.9 million and a median of $18.1 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 90.35% in 2022 and decreased 22.8% in 2025, its largest moves.
• Tracing NAUT's Operating Expenses over 5 years: stood at $16.3 million in 2022, then climbed by 22.68% to $20.0 million in 2023, then retreated by 0.1% to $20.0 million in 2024, then declined by 22.8% to $15.4 million in 2025, then grew by 4.54% to $16.1 million in 2026.
• Business Quant data shows NAUT's Operating Expenses at $16.1 million in Q1 2026, $15.4 million in Q4 2025, and $15.5 million in Q3 2025.